Shipping Industry was one of the hottest stock market segments today. Some of the market analysts believe that the spike in share prices is a response to the Baltic Dry Index (BDI), which is going into a positive territory since been trampled at the 2012. Anyhow, looks like bottom has been formed in the one […]
Amicus Therapeutics (FOLD) has been profiled as a bounce play from December 31th, 2012. Since then FOLD shares gained over 50% (as of now) and have continued their march to the new highs. Today Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the […]
Aeterna Zentaris Inc. (AEZS) On December 28th Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. Optimistic market reaction on this announcement boosted AEZS shares […]
Magnum Hunter Resources Corporation (NYSE: MHR) today announced production results from its two new Eagle Ford Shale wells that have been on production since December 22, 2012. Mr. Gary C. Evans, Chairman and Chief Executive Officer of Magnum Hunter Resources Corporation, noted: These two new Eagle Ford wells are by far our best producers since […]
Cellceutix Corporation stock (CTIX) had impressive run from low 80 cents to over $2.40 in a month+. CTIX stock is in overbought condition (that’s obvious) but most important that it is heavily overvalued. Take a brief look at company’s products and its financials: 1. Cellceutix’s psoriasis compound, Prurisol™ Prurisol is a small molecule, acting on […]
Tranzyme, Inc. (TZYM) announced today that its drug candidate, TZP-102, did not meet its primary efficacy endpoint. Tranzyme’s Phase IIb study was for two doses of TZP-102 taken once daily against a placebo. Even all patients saw a reduction in gastroparesis symptoms after 12 weeks of treatment, the difference between TZP-102 and placebo was minimum […]
MRI Interventions (MRIC), a company with a revolutionary ClearPoint system that enables neurosurgeons to see inside the brain in real-time using direct MRI guidance while performing minimally invasive surgical procedures, today released strong 2012 third quarter (Q3) financial results. To-date, MRI Interventions has successfully implemented its ClearPoint system in 18 sites with the first case […]
Guided Therapeutics, Inc. (GTHP) today announced that it has submitted to FDA its PMA (premarket approval amendment) for the LuViva Advanced Cervical Scan (a non-invasive device used to detect cervical disease that leads to cancer). LuViva has been under FDA PMA review since September 23, 2010. FDA declined LuViva in January 20, 2012. In July, […]
Tekmira Pharmaceuticals Corporation (TKMR) announced today that it has entered into a settlement agreement with Alnylam Pharmaceuticals, Inc. that resolves all litigation between the companies. Tekmira will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013 as a result of the […]
This is our early-bird alert on MRI Interventions (MRIC), a company we profiled back in June when it had just emerged in the market. By ‘early-bird’ we mean notice before the stock experiences what we believe will be a big run-up in price. If you weren’t following us earlier this year, we called MRIC at […]
